Intellia Therapeutics’ (NTLA) Neutral Rating Reiterated at Wedbush

Wedbush reaffirmed their neutral rating on shares of Intellia Therapeutics (NASDAQ:NTLA) in a research report report published on Monday morning,Benzinga reports. They currently have a $10.00 target price on the stock.

A number of other brokerages have also commented on NTLA. JPMorgan Chase & Co. reaffirmed a “neutral” rating and set a $13.00 price objective (down previously from $45.00) on shares of Intellia Therapeutics in a research report on Friday, February 28th. Wells Fargo & Company cut their price objective on shares of Intellia Therapeutics from $60.00 to $50.00 and set an “overweight” rating for the company in a research report on Friday, February 28th. Wolfe Research raised shares of Intellia Therapeutics from a “peer perform” rating to an “outperform” rating and set a $21.00 price objective for the company in a research report on Monday, April 21st. Barclays cut their price objective on shares of Intellia Therapeutics from $55.00 to $26.00 and set an “overweight” rating for the company in a research report on Friday, February 28th. Finally, The Goldman Sachs Group reaffirmed a “sell” rating and set a $9.00 price objective on shares of Intellia Therapeutics in a research report on Friday, February 28th. Two equities research analysts have rated the stock with a sell rating, six have assigned a hold rating, thirteen have issued a buy rating and one has given a strong buy rating to the company. Based on data from MarketBeat.com, Intellia Therapeutics has a consensus rating of “Moderate Buy” and a consensus target price of $36.90.

Intellia Therapeutics Price Performance

Intellia Therapeutics stock opened at $9.20 on Monday. The firm has a market cap of $952.96 million, a price-to-earnings ratio of -1.69 and a beta of 2.33. Intellia Therapeutics has a fifty-two week low of $5.90 and a fifty-two week high of $28.18. The firm has a fifty day moving average price of $7.99 and a two-hundred day moving average price of $10.67.

Intellia Therapeutics (NASDAQ:NTLA) last announced its quarterly earnings data on Thursday, May 8th. The company reported ($1.10) EPS for the quarter, beating analysts’ consensus estimates of ($1.26) by $0.16. The company had revenue of $16.63 million for the quarter, compared to analyst estimates of $11.39 million. The firm’s quarterly revenue was down 42.6% on a year-over-year basis. During the same period in the prior year, the company posted ($1.12) EPS. As a group, sell-side analysts expect that Intellia Therapeutics will post -5.07 earnings per share for the current year.

Institutional Trading of Intellia Therapeutics

A number of institutional investors and hedge funds have recently added to or reduced their stakes in the business. Ensign Peak Advisors Inc increased its stake in Intellia Therapeutics by 2.9% in the fourth quarter. Ensign Peak Advisors Inc now owns 39,169 shares of the company’s stock valued at $457,000 after acquiring an additional 1,100 shares during the period. HighTower Advisors LLC grew its stake in Intellia Therapeutics by 8.2% during the first quarter. HighTower Advisors LLC now owns 16,921 shares of the company’s stock worth $120,000 after buying an additional 1,282 shares during the last quarter. Allspring Global Investments Holdings LLC grew its stake in Intellia Therapeutics by 14.0% during the fourth quarter. Allspring Global Investments Holdings LLC now owns 12,863 shares of the company’s stock worth $157,000 after buying an additional 1,582 shares during the last quarter. Arizona State Retirement System grew its stake in Intellia Therapeutics by 6.1% during the fourth quarter. Arizona State Retirement System now owns 28,006 shares of the company’s stock worth $327,000 after buying an additional 1,615 shares during the last quarter. Finally, E Fund Management Co. Ltd. grew its stake in Intellia Therapeutics by 10.0% during the fourth quarter. E Fund Management Co. Ltd. now owns 18,053 shares of the company’s stock worth $210,000 after buying an additional 1,634 shares during the last quarter. Institutional investors own 88.77% of the company’s stock.

Intellia Therapeutics Company Profile

Intellia Therapeutics, Inc, a genome editing company, focuses on the development of curative therapeutics. The company's in vivo programs include NTLA-2001, which is in Phase 1 clinical trial for the treatment of transthyretin amyloidosis; NTLA-2002 for the treatment of hereditary angioedema; and NTLA-3001 for alpha-1 antitrypsin deficiency associated lung disease.